Skip to main content
The Lancet Regional Health - Southeast Asia logoLink to The Lancet Regional Health - Southeast Asia
. 2025 Aug 15;40:100650. doi: 10.1016/j.lansea.2025.100650

Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial

Watsamon Jantarabenjakul a,b,c, Rapisa Nantanee a,b, Thanyawee Puthanakit a,b, Sivaporn Gatechompol d, Anchalee Avihingsanon d, Suda Punrin e, Terapong Tantawichien e,f, Sorachai Nitayaphan g, Arunee Thitithanyanont h, Supranee Buranapraditkun i,j, Anan Jongkaewwattana k, Chutitorn Ketloy i,l, Eakachai Prompetchara i,k, Saranath Lawpoolsri m,n, Wassana Wijagkanalan o, Mohamad-Gabriel Alameh p, Lina Hong q, Mijo Samija r, Drew Weissman s, Kiat Ruxrungtham i,j,t,∗; ChulaVac006 Study Teamu, on behalf of
PMCID: PMC12390948  PMID: 40895389

Summary

Background

Strengthening mRNA vaccine development in LMICs is essential for enhancing global pandemic preparedness. This study evaluated the safety and immunogenicity of Comvigen, a bivalent SARS-CoV-2 vaccine, in comparison to the Comirnaty bivalent vaccine (Comirnaty).

Methods

This phase II, randomised, open-label, non-inferiority trial was conducted in Thailand across four centres. Participants (n = 450) were randomly assigned (2:1) to receive either Comvigen (50 μg) or Comirnaty (30 μg), using block randomisation (size = 9). Eligible participants had completed at least 2 doses of any approved COVID-19 vaccine, with the last mRNA-vaccine dose given over 3 months before enrolment. The non-inferiority margin of a geometric mean ratio (GMR) of 0.67. The primary immunogenicity endpoint was pseudovirus neutralisation titres (psVNT-50) against SARS-CoV-2 wild-type and Omicron BA.4/BA.5 at Day 29. Safety outcomes included local and systemic adverse reactions up to six months post-vaccination. Immunogenicity analyses were conducted on the Per-Protocol (PP) population and the modified Intent-to-Treat (mITT) population; safety analyses included all participants. Laboratory personnel were blinded to vaccine assignment (ClinicalTrials.gov: NCT05930730).

Findings

Between October and November 2023, 450 participants were enrolled (median age of 36 years, IQR 30–45). At day 29, the geometric mean titre (GMT) of psVNT-50 against wild-type virus increased from 475.9 to 2062.9 for Comvigen and from 458.8 to 1905.1 for Comirnaty (GMR 1.1, 95% CI: 1.0–1.2), meeting non-inferiority criteria. Against Omicron BA.4/BA.5, GMTs were 3909.8 for Comvigen and 3288.6 for Comirnaty (GMR 1.2, 95% 1.0–1.4). Local and systemic reactions were more frequent with Comvigen (91% vs. 78%, p = 0.0002, 79% vs. 70%, p = 0.028) but were mild or moderate and transient with no difference in fever (6% vs. 5%, p = 0.84).

Interpretation

Comvigen demonstrated non-inferiority immunogenicity to Comirnaty and had a comparable safety profile, supporting mRNA vaccine development for global access and pandemic preparedness.

Funding

Covid-19 Pandemic Emergency Fund granted by Thailand's National Economic and Social Development Council provided major funding. Supplementary funding was provided by National Vaccine Institute (NVI), Thailand; Center of Excellence in Vaccine Research and Development (Chula VRC), Faculty of Medicine, Chulalongkorn University; Chulalongkorn University Second Century Fund (C2F); BioNet-Asia and Public Donation through Covid-19 vaccine development fund of the Faculty of Medicine, Chulalongkorn University and the Thai Red Cross Society, Thailand.

Keywords: COVID-19 vaccine booster, Immunogenicity, Safety, Omicron, mRNA vaccine, Pandemic preparedness, Vaccine equity, Neutralising antibody, T-cells


Research in context.

Evidence before this study

We searched PubMed, medRxiv, and major preprint servers for studies published in English from January to August 2023 using the terms “mRNA vaccine,” “SARS-CoV-2”, “bivalent vaccine”, and “COVID-19 booster”. Previous studies demonstrated the efficacy of mRNA vaccines against COVID-19 but highlighted global inequities in vaccine access, manufacturing, and distribution. While bivalent mRNA vaccines targeting SARS-CoV-2 variants have been widely used, data on their development and evaluation in LMICs remain limited. The first-generation ChulaCov19, a monovalent vaccine (50 μg), demonstrated safety and high immunogenicity in Phase I/II trials.

Added value of this study

The second-generation bivalent vaccine, Comvigen (ChulaCov19 BNA159.2), was developed in response to Omicron variants and manufactured in Thailand. This Phase II randomised, open-label, non-inferiority trial provides comparative immunogenicity and safety data on Comvigen, developed in an LMIC setting. Comvigen demonstrated non-inferior immunogenicity against both wild-type and Omicron BA.4/BA.5 compared to Comirnaty, a widely used mRNA vaccine. Safety outcomes were comparable, with transient and manageable adverse reactions. This study serves as a model for regional mRNA vaccine development in LMICs, addressing critical gaps in global pandemic preparedness.

Implications of all the available evidence

The findings support the feasibility of LMIC-led mRNA vaccine development, which could enhance regional vaccine security and equitable access. The demonstrated non-inferiority of Comvigen suggests that locally manufactured mRNA vaccines can provide effective immunity against emerging variants. These results underscore the need for continued investment in LMIC-based vaccine research and infrastructure to strengthen global health resilience against future pandemics.

Introduction

During the SARS-CoV-2 pandemic, mRNA vaccine platforms played a pivotal role due to their rapid scalability and ability to induce strong humoural and cellular immune responses.1 Over 13.6 billion vaccine doses had been administered globally by the end of 2023.2 However, vaccine distribution remained highly unequal: while more than 70% of individuals in high-income countries received at least complete primary vaccination, this figure dropped to less than 30% in developing countries.3 This inequity access has been repeatedly happening in all pandemics in the past, and confirming that pandemic preparedness and response could not rely primarily on market dynamics to drive development and availability of vaccine and critical new health products. Transformative strategies for public good driven has been proposed and implementing by expanding mRNA vaccine research and development as well as manufacturing capabilities in low- and middle-income countries (LMICs) is therefore critical to improving equity during this and future pandemics.4,5

Thailand is committed to advancing equitable vaccine access as part of this transformative mission. During the COVID-19 pandemic, the Vaccine Research Center at Chulalongkorn University launched the ChulaCov19 mRNA vaccine development programme to enhance regional capacity for mRNA vaccine research, production, clinical evaluation, and regulatory approval. This initiative aims to improve pandemic preparedness and ensure timely vaccine access in low- and middle-income countries (LMICs). The program is supported by both the Thai government and public donations.

Preclinical and Phase 1–2 clinical studies of the first-generation monovalent ChulaCov19 mRNA vaccine—targeting the original Wuhan strain and manufactured by a U.S.-based contract manufacturing organisation—demonstrated promising immunogenicity and safety profiles when compared to an approved mRNA vaccine.6, 7, 8 Notably, the ChulaCov19 vaccine encoded the non-stabilised ectodomain of the spike protein rather than the full-length version, and it did not include the commonly used di-proline mutation seen in currently approved COVID-19 mRNA vaccines. In addition, it employs a distinct lipid nanoparticle (LNP) formulation.7

Before advancing to Phase 3 trials, the emergence of the Omicron variant9 prompted a strategic shift. A new bivalent mRNA vaccine, encoding both Wuhan and Omicron spike proteins, was developed in parallel. This effort also supported the development of domestic mRNA vaccine manufacturing capabilities.

In this study, we present Phase 2 safety and immunogenicity data, as a booster, of the bivalent COVID-19 vaccine, Comvigen, developed and manufactured in Thailand. The vaccine is evaluated in comparison to the approved bivalent Comirnaty vaccine.

Methods

Study design

This is a phase II randomised non-inferior open-label trial (study number: Chulavac006, NCT05930730). A total of 450 healthy participants aged 18–64 years were enrolled at four sites in Bangkok, Thailand: Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University; HIV Netherlands Australia Thailand Research Collaboration (HIVNAT), Thai Red Cross AIDS Research Center; Armed Forces Research Institute of Medical Sciences (AFRIMS); and Queen Saovabha Memorial Institute (QSMI).

Participants

Potential participants providing voluntary written informed consent were screened for eligibility within 30 days prior to study vaccination. Eligible participants had completed a primary course of at least 2 doses of any approved COVID-19 vaccine, with the last dose being mRNA-based and administered more than 3 months before enrolment. Participants were required to agree to effective contraception for two months after vaccination for males and three months for females. Exclusion criteria included recent COVID-19 infection, immunosuppression, history of severe vaccine reactions, significant medical conditions, or prior receipt of any vaccine, immunoglobulins, or blood products within specific timeframes. Screening involved medical history review, physical examination, laboratory tests, SARS-CoV-2 antigen testing, and pregnancy testing for females. Screening procedures included a review of medical history, physical examination, and laboratory testing (complete blood count, coagulation profile, renal/liver function tests, and urinalysis). Before vaccination, participants underwent SARS-CoV-2 rapid antigen testing, and females underwent a urine pregnancy test.

Randomisation and procedures

On the vaccination visit, participants were randomised 2:1 to receive Comvigen (bivalent original/Omicron BA.4-5 “ChulaCoV19 BNA159.2”) or Comirnaty (Pfizer) using block randomisation (block size: nine). The allocation sequence was generated by an independent statistician and implemented via a centralised, web-based system to ensure allocation concealment prior to assignment.

Blood samples were collected pre-vaccination, at 29 days, and 6 months after vaccination to evaluate immunogenicity. Participants recorded solicited local and systemic adverse events daily using electronic diaries for 7 days post-vaccination. For participants unable to use electronic diaries, paper diary cards were provided, with a follow-up phone call on Day 8. Adverse events were collected though 28 days, while serious adverse events (SAEs), medically attended adverse events (MAAEs), and new-onset chronic medical conditions (NOCMCs) were monitored for 6 months.

Trial vaccine

Comvigen (ChulaCov19 BNA159.2 mRNA vaccine, Lot No. C004A1) is a bivalent mRNA vaccine (ChulaCov19 BNA159 mRNA and Chulacov19 BNA187 mRNA 1:1) encoding a non-stabilised Wuhan and a 2P-stabilised Omicron BA.4/BA.5 SARS-CoV-2 secreted spike proteins, encapsulated in the same LNP formulation (licenced from Genevant Science GmbH, Switzerland) used for the ChulaCov19 BNA159 vaccine.7,8 The lipid composition contained PEG2000-C-DMA,10 Lipid 10 cholesterol,11 and DSPC at a mol ratio of 1.5:50:38.5:10 respectively.12 Comvigen was manufactured by BioNet-Asia, Thailand, under GMP conditions and supplied in multi-dose vials. After dilution, Comvigen was administered intramuscularly at deltoid region at a 50 μg/0.5 ml dose. This dose was selected based on the results of a previous phase 1–2 clinical study (Protocol number ChulaVac 001; ClinicalTrials.gov: NCT04566276).7 Comirnaty bivalent Wuhan/Omicron BA.4-5 (Pfizer) was administered intramuscularly at 30 μg/0.3 ml.

Outcomes

The primary immunogenicity assessment included SARS-CoV-2-specific serum-neutralising antibodies measured by pseudoviral neutralisation assay (psVNT-50) against wild-type and Omicron BA.4/BA.5 at Day 29. Secondary immunogenicity assessment included (1) live-virus microneutralisation assay (micro-VNT-50) against wild-type. (2) Wild type SARS-CoV-2 anti-receptor binding domain (anti-RBD) and anti-spike (anti-S) IgG titres using Enzyme-Linked Immunosorbent Assay (ELISA); and (3) SARS-CoV-2 S specific T-cell responses measured by IFN-Gamma Enzyme-Linked Immune Absorbent Spot (ELISpot) assay using peripheral blood mononuclear cells (PBMCs) stimulated with overlapping peptide pool spanning the full-length Spike (S) glycoprotein of the ancestral strain (from the first half of participants) at Day 29.7 A follow-up visit was conducted on Day 169 (6 months post-booster) for safety and immunogenicity assessment. Laboratory personnel were blinded to vaccine assignment.

Protocol deviations

The original protocol listed additional secondary objectives involving broader variant-specific immunogenicity assessment using pseudovirus neutralisation test (psVNT-50) and micro-viral neutralisation test (MicroVNT). Specifically, it proposed measuring neutralising antibody titres against variants beyond Omicron BA.4/5 (for psVNT-50) and including Omicron BA.4/5 (for MicroVNT). However, due to the decline in COVID-19 transmission and changes in public health priorities during the study period, along with financial constraints, these extended assays were not pursued. Instead, psVNT-50 was performed only against the wild-type and Omicron BA.4/5 strains, and MicroVNT was conducted against the wild-type strain only. This decision was made prior to data analysis and was based on feasibility and cost considerations.

Statistical analysis

Sample size calculation

The sample size determination was based on immunobridging analysis using psVNT-50 results against wild-type virus, measured 4 weeks after a booster dose of either the Comvigen or bivalent Comirnaty vaccine. Non-inferiority was defined as the lower bound of the 95% confidence interval (CI) for the Geometric mean ratio (GMR) being greater than 0.67.13 Assuming a GMR of 0.90, the non-inferiority margin of 0.67, and the log scale standard deviation (SD) of 0.89, derived from a previous phase 2 study comparing the ChulaCov19 and Pfizer vaccines,8 with one-sided alpha 0.025, power 90%, and a 2:1 ratio, the required sample size is 432 participants (Comvigen: 288; Comirnaty: 144). To address both hypotheses and account for 4% dropout, the final sample size is 450 participants (Comvigen: 300, Comirnaty: 150).

Safety and immunogenicity analysis

The Safety Analysis Set was used for all safety endpoints. Immunogenicity analyses were conducted on the Per-Protocol (PP) population and the modified Intent-to-Treat (mITT) population. The per-protocol population comprised those in the mITT set who adhered fully to the study protocol without major deviations affecting the primary outcome. The modified intent-to-treat (mITT) population included all participants who received either study vaccine and had at least one post-baseline immunogenicity assessment, excluding those with virologic or immunologic evidence of prior SARS-CoV-2 infection up to the time of evaluation. Participants were analysed according to their randomised assignment, regardless of the actual vaccine received. The primary safety endpoints included solicited local and systemic reactogenicity adverse events (AEs) from Day 1 to Day 7 post-vaccination, and unsolicited AEs through Day 29. Longer-term safety assessments included SAEs, MAAEs, and NOCMCs, monitored for six months.

The primary immunogenicity endpoints evaluated GMTs and geometric mean fold rises (GMFRs) of psVNT-50 against wild-type and Omicron BA.4/BA.5 at Day 29, as well as seroconversion rates (≥4-fold rise). The secondary immunogenicity endpoints included the micro-VNT50 against wild type, the geometric mean concentration (GMC) and GMFR of anti-RBD IgG and anti-spike IgG, reported in binding antibody units (BAU)/mL and seroconversion. T-cell responses were measured by IFN-Gamma ELISpot reported in median spot-forming cells (SPF) per 1 million PBMCs and fold rises.

Descriptive statistics were used to summarise baseline characteristics and safety outcomes. For the comparison of adverse reactions between the Comvigen and Comirnaty groups, two-sided 95% confidence intervals (CIs) for proportions were calculated using the Clopper-Pearson method. p-values for comparisons between groups were calculated using two-sided Chi-square tests. All reported p-valued are presented with two significant digits; any p-value less than 0.0001 is reported as <0.0001.

Immunogenicity analyses were conducted in both the PP and mITT. Immunogenicity outcomes are summarised using geometric mean titres (GMTs), geometric means fold rise (GMFR) from baseline, 95% CIs for GMTs and GMFRs, and the proportion of participants achieving seroconversion. Antibody seroconversion was defined as a ≥4-fold rise from the baseline, with a post-vaccination titre/concentration > the assay's positive cut-off. For GMFR and GMT calculations, values below one were replaced with one. For participants with baseline titre ≥1, actual values were used in the GMFR calculation. Estimation of GMTs and GMFRs involved log-transformation, with back-transformed coefficients used to report final estimates and their 95% CIs. For binary immunogenicity outcomes (e.g., seroconversion), 95% CIs were computed using the Clopper–Pearson method. The distribution of antibody tits was also visualised using reverse cumulative distribution curves. All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA).

Ethics approval

This study was approved by ethics committee of each study site (Chula CRC IRB No. 0463/66; HIVNAT IRB No. 0456/66; IRBTA No. 1154/2566; QSMI-IRB No. 5/2023).

Role of funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Baseline characteristic

Between October and November 2023, 502 individuals were screened for participation, with 300 enrolled in the Comvigen group and 150 in the Comirnaty group. After randomisation, three participants were excluded, including one Comvigen participant with a prior COVID-19 vaccine dose, one enrolled in another investigational study, and one Comirnaty participant who mistakenly received Comvigen. No participants missed follow-ups, but one Comvigen participant missed the blood test, and one Comirnaty participant withdrew on Day 169. Consequently, the Safety Analysis Set included 300 participants for Comvigen and 150 for Comirnaty. In comparison, the mITT primary endpoint analyses included 299 participants for Comvigen and 149 for the Comirnaty group, and PP analyses included 298 participants for Comvigen and 149 for Comirnaty (Fig. 1).

Fig. 1.

Fig. 1

Flow diagram of study participants. †Other reasons for ineligibility included (1) not agree to refrain from donating blood, plasma, ova, sperm, or organs during the whole study (n = 1), (2) immunosuppressed as caused by disease or immunosuppressive therapy or anticipated need to use of any chemotherapy or immunosuppressive agents within the next 6 months (n = 1), (3) bleeding disorders or taking an anticoagulant or anti-platelet agent that may contraindicate for intramuscular injection based on investigator's judgement (n = 1), and (4) received any prophylactic or therapeutic vaccine, biologic product, device or blood product, within 4 weeks of vaccination or 5 half-lives (whichever is longer), or anticipate doing so in the follow-up period defined for this study (n = 1). Abbreviations: mITT: modified intent-to-treat; PP: per-protocol.

The median age (interquartile range [IQR]) was 36 years (30–44) in the Comvigen group and 35 years (29–46) in the Comirnaty group. A history of COVID-19 infection was reported by 73% and 61% of Comvigen and Comirnaty participants, respectively. Participants had received between two and eight doses of COVID-19 vaccine prior to the study. Most participants received two doses of CoronaVac™ (inactivated virus vaccine, Sinovac) or Vaxzevria™ (ChAdOx-1S, AstraZeneca) as the primary series, followed by the two booster doses of either Comirnaty™ (BNT162b2, Pfizer-BioNTech), Vaxzevria™, or SpikeVax™ (mRNA-1273, Moderna). The median (IQR) duration between the last dose and the study vaccine was 17 (12–21) months. Baseline characteristics were comparable between the two groups (Table 1 and Supplement Table S1).

Table 1.

Demographic data of study participants.

Characteristics, n (%) All (N = 450) Vaccine groups
Comvigen (N = 300) Comirnaty (N = 150)
Sex: male 214 (47.6%) 153 (51.0%) 61 (40.7%)
Age (years), mean (SD) 37.6 (9.9) 37.7 (9.5) 37.5 (10.5)
Race: Thai 450 (100.0%) 300 (100.0%) 150 (100.0%)
BMI (kg/m2), mean (SD) 25.0 (4.6) 25.0 (4.6) 24.9 (4.6)
History of COVID-19 infection 311 (69.1%) 220 (73.3%) 91 (60.7%)
Underlying medical conditions
 Hypertension 32 (7.1%) 23 (7.7%) 9 (6.0%)
 Dyslipidemia 29 (6.4%) 21 (7.0%) 8 (5.3%)
 Allergic rhinitis 20 (4.4%) 16 (5.3%) 4 (2.7%)
 Diabetes mellitus 12 (2.7%) 8 (2.7%) 4 (2.7%)
Number of COVID-19 vaccine doses received prior to the study, median (IQR) 4.0 (3.0–5.0) 4.0 (3.0–5.0) 4.0 (3.0–5.0)
Number of COVID-19 vaccine doses received prior to the study
 2 doses 20 (4.4%) 15 (5.0%) 5 (3.3%)
 3 doses 122 (27.1%) 80 (26.7%) 42 (28.0%)
 4 doses 145 (32.2%) 95 (31.7%) 50 (33.3%)
 ≥5 doses 163 (36.2%) 110 (36.7%) 53 (35.3%)
Duration between last dose and study vaccination (months), median (IQR) 16.8 (12.1–21.1) 16.8 (12.2–21.2) 16.6 (12.1–20.8)

Safety and tolerability

Solicited local and systemic reactions from Day 1 to Day 7 post-vaccination are presented in Fig. 2 and Supplement Table S2. Local reactions were reported in 91% (95% CI: 87–94%) of Comvigen participants and 78% (95% CI: 71–84%) of Comirnaty participants (p = 0.0002). The most common local reaction was pain at the injection site, predominantly mild (57%) or moderate (28%). Systemic reactions during 30 min post-vaccination occurred in 14% of participants in both groups. From Day 1 to Day 7, systemic reactions were higher in the Comvigen group (79%, 95% CI: 74–84%) compared to Comirnaty (70%, 95% CI: 62–77%) (p = 0.03). Fatigue, muscle pain, and headache were the most frequently reported systemic reactions. The fever rate was similar (6% vs. 5%, p = 0.88). Most systemic reactions were mild (52%), with a few cases of moderate severity (22%). Systemic symptoms were transient, with a mean duration of 2.5 days in both groups.

Fig. 2.

Fig. 2

Local and systemic solicited adverse reactions within 7 days after vaccination with Comvigen (50 μg) and Comirnaty (30 μg).

Adverse events (AEs) within 29 days were reported by 76 participants: 57 (19%) in the Comvigen group and 19 (13%) in the Comirnaty group. Vaccine-related AEs grade 1–2 occurred in 19 participants. One Comvigen participant experienced acute intermittent urticaria (grade 1) on day 12 that resolved with antihistamines within two months. One serious adverse event (SAE), possibly vaccine-related, involved a Comvigen participant with acute costochondritis, presenting as chest pain without evidence of myocarditis. The participant improved within 24 h after symptomatic treatment. In brief, the participant was a 26-year-old male with a medical history of hypertension and hyperthyroidism. He had previously received two doses of Vaxzevria™ and one dose of Comirnaty™ as a booster, administered 29 months prior to enrolment. On Day 15 post-vaccination, he presented with chest pain and was subsequently diagnosed with acute costochondritis. There was no evidence of myocarditis, as electrocardiogram (ECG) findings revealed no significant ST-T changes and cardiac enzyme levels were within normal limits. The condition improved with symptomatic treatment (Non-steroid anti-inflammatory) and resolved by the following day. Eighteen MAAEs were reported, including one case of Bell's palsy in a Comvigen participant, which resolved after a 7-day prednisolone course. Nine NOCMCs (six in Comvigen, three in Comirnaty) included hyperthyroidism, hypertension, dyslipidemia, and gout, all deemed unrelated to the vaccines [Supplement Table S2].

Immunogenicity findings

Pseudovirus neutralisation test against wild type virus (WT) and Omicron BA.4/BA.5

At baseline, GMTs of pseudovirus neutralisation test with 50% inhibition titre (psVNT50) against wild-type virus were 476 (95% CI: 427–530) for Comvigen and 459 (95% CI: 377–559) for Comirnaty. By Day 29 post-immunisation, GMTs increased to 2063 (95% CI: 1906–2232) for Comvigen and 1905 (95% CI: 1713–2119) for Comirnaty, with a GMR of 1.08 (95% CI: 0.95–1.24), meeting non-inferiority criteria. The GMFR was 4.3 for Comvigen and 4.2 for Comirnaty, with 49% and 39% seroconversion rates, respectively (p = 0.06). At six months, GMTs declined to similar levels in both groups [Table 2, Fig. 3].

Table 2.

Immunogenicity to SARS-CoV-2 by pseudovirus neutralisation test with 50% inhibition titre (psVNT50) against wild type virus (WT) and Omicron BA.4/BA.5, and live-virus neutralisation test with 50% inhibition titre (MicroVNT50) against wild type virus (WT) in modified intent-to-treat (mITT) and per-protocol (PP) population.

mITT
PP
Comvigen
Comirnaty
GMR Comvigen
Comirnaty
GMR
n GMT (95% CI) GMFR (95% CI) n GMT (95% CI) GMFR (95% CI) n GMT (95% CI) GMFR (95% CI) n GMT (95% CI) GMFR (95% CI)
psVNT50 against wild-type virus (WT)
 Baseline 299 475.9 (427.2–530.2) – 149 458.8 (376.7–558.7) – – 298 474.7 (426.0–528.9) – 149 458.8 (376.7–558.7) –
 Post-vaccination 28 days 299 2062.9 (1906.4–2232.4) 4.3 (3.9–4.8) 149 1905.1 (1712.8–2119.0) 4.2 (3.5–5.0) 1.1 (1.0–1.2) 298 2065.4 (1908.2–2235.6) 4.4 (3.9–4.8) 149 1905.1 (1712.8–2119.0) 4.2 (3.5–5.0) 1.1 (1.0–1.2)
 Post-vaccination 6 months 298 534.9 (490.0–583.9) 1.1 (1.0–1.3) 148 540.8 (475.4–615.3) 1.2 (1.0–1.4) 1.0 (0.9–1.2) 297 534.8 (489.8–583.9) 1.1 (1.0–1.3) 148 540.8 (475.4–615.3) 1.2 (1.0–1.4) 1.0 (0.9–1.2)
psVNT50 against Omicron BA.4/BA.5a
 Post-vaccination 28 days 299 3909.8 (3515.0–4348.8) – 149 3288.6 (2826.2–3826.8) – 1.2 (1.0–1.4) 298 3916.4 (3519.9–4357.5) – 149 3288.6 (2826.2–3826.8) – 1.2 (1.0–1.4)

Abbreviations: GMFR: Geometric Mean Fold Rise from baseline; GMR: Geometric Mean Ratio (GMR) Comvigen/Comirnaty; GMT: Geometric Mean Titre; mITT: modified intent-to-treat; PP: per-protocol.

a

The baseline psVNT against Omicron BA.4/BA.5 was not included in the protocol.

Fig. 3.

Fig. 3

Immunogenicity results of SARS-CoV-2 pseudovirus neutralisation test with 50% inhibition titre (psVNT50) against (A) geometric mean titre (GMT) against wild-type virus, (B) GMT against Omicron BA.4/BA.5, (C) geometric mean ratio (GMR) against wild-type virus, and (D) GMR against Omicron BA.4/BA.5 in modified intent-to-treat (mITT) population.

Omicron BA.4/BA.5 GMTs on Day 29 were 3910 (95% CI: 3515–4349) for Comvigen and 3289 (95% CI: 2826–3827) for Comirnaty. The GMR comparing Comvigen to Comirnaty on Day 29 was 1.19 (95% CI: 0.99–1.43), confirming a non-inferiority outcome [Table 2, Fig. 3].

Live-virus neutralisation test with 50% inhibition titre (MicroVNT50)

Baseline GMTs against wild-type virus were comparable between groups. By Day 29, GMTs increased to 1190 for Comvigen and 1133 for Comirnaty, with a GMR of 1.05 (95% CI: 0.89–1.23). This confirms non-inferiority; however, the lower bound of the confidence interval did not exceed the predefined superiority margin of 1.01, and thus the criterion for superiority was not met. The GMFRs were slightly higher for Comvigen (5.8) than for Comirnaty (5.5). At six months, GMTs declined to similar levels, indicating comparable durability [Supplement Table S3, Fig. 4A].

Fig. 4.

Fig. 4

Immunogenicity results: (A) microVNT50 against wild type virus in geometric mean titre (GMT) with 95% CI; (B) SARS-CoV-2-RBD-binding IgG antibody measured by Enzyme-Linked Immunosorbent Assay (ELISA) in geometric mean titre (GMT) with 95% CI; (C) anti-spike antibody in geometric mean titre (GMT) with 95% CI; (D) SARS-CoV-2 spike protein specific T-cell responses measured by IFN-gamma ELISpot assay (SFC per 106 PBMCs) in median with IQR; in modified intent-to-treat (mITT) population.

SARS-CoV-2-RBD-binding IgG antibody measured by Enzyme-Linked Immunosorbent Assay (ELISA)

Baseline GMCs of anti-RBD IgG antibodies were 984 BAU/mL for Comvigen and 1023 BAU/mL for Comirnaty. By Day 29, GMCs increased to 5776 for Comvigen and 5493 for Comirnaty, with a GMR of 1.1 (95% CI: 0.9–1.2). GMFRs were slightly higher for Comvigen (5.9) than for Comirnaty (5.4). At six months, GMCs declined to similar levels in both groups [Supplement Table S4, Fig. 4B].

Anti-spike antibody

Baseline GMCs of anti-spike antibodies were 1289 BAU/mL for Comvigen and 1325 BAU/mL for Comirnaty. By Day 29, GMCs rose to 7007 for Comvigen and 6516 for Comirnaty, with a GMR of 1.08 (95% CI: 0.96–1.20), indicating comparable antibody responses. At six months, GMCs declined to 2513 for Comvigen and 2666 for Comirnaty, with a GMR of 0.9 (95% CI: 0.8–1.1) [Supplement Table S4, Fig. 4C].

SARS-CoV-2 specific T cell response by IFN-Gamma Enzyme-Linked Immune Absorbent Spot (ELISpot) assay

Baseline median spot-forming cells (SFC) counts per million PBMCs were 264 for Comvigen and 272 for Comirnaty. By Day 29, SFC counts increased to 656 for Comvigen and 584 for Comirnaty. The GMFRs were 2.4 for Comvigen and 2.2 for Comirnaty, indicating robust cellular responses in both groups, with slightly higher responses in the Comvigen group [Supplement Table S5, Fig. 4D].

Discussion

A COVID-19 vaccine booster is critical to address evolving SARS-CoV-2 variant and waning immunity. Comvigen, a bivalent mRNA vaccine developed by Chula VRC to strengthen vaccine development capacity, demonstrated non-inferiority to Comirnaty in eliciting both humoural and cellular immunity. While Comvigen was associated with a slightly higher rate of local and systemic reactions, they were mild and transient, supporting its potential as a booster vaccine.

Both Comvigen and Comirnaty demonstrated favourable safety profiles, with no vaccine-related serious adverse events and no local or systemic adverse events exceeding grade 3 severity. Local reactions, primarily injection-site pain, were more frequently reported in the Comvigen group compared to Comirnaty during the 7 days post-vaccination (91% vs. 78%), though the severity was mostly mild to moderate and transient. Similarly, systemic reactogenicity—such as fatigue, headache, and muscle pain—was more common in the Comvigen group (79% vs. 70%), but these events were short-lived, with an average duration of approximately 2.5 days in both groups. While vomiting and diarrhoea were slightly more common in the Comvigen group (5% and 9%, respectively, vs. 1% and 4%), all events resolved without complication. Overall, the slightly higher reactogenicity in the Comvigen group was consistent with robust immunogenicity and remained within acceptable tolerability parameters.

A higher rate of local and systemic reactions in the Comvigen arm compared to Comirnaty may be attributed to its higher dose (50 μg vs. 30 μg). This observation aligns with Phase I studies of the first-generation ChulaCov vaccine, which showed a dose-dependent increase in reactogenicity.7 Additionally, when compared to mRNA 1273.222 (50 μg) previous reported rate, Comvigen exhibited a slightly higher incidence of local reactions (91% vs. 83%) and systemic reactions (79% vs. 73%).14

One SAE possibly related to Comvigen involved a case of acute costochondritis, a benign inflammatory chest wall condition. This resolved quickly with symptomatic treatment, consistent with prior reports of vaccine-related costochondritis, which are rare and less severe than cases linked to COVID-19 infection.15 A case report of post-COVID-19 costochondritis was more severe than vaccine-related costochondritis.16 Additionally, one case of Bell's palsy occurred on Day 52 post-vaccination. This timeline is outside the usual follow-up range of 7–43 days, as reported in several studies.17 Meta-analyses indicated a slightly higher incidence of Bell's palsy in vaccinated individuals compared to those receiving placebo, but no significant difference was found between BNT162b2 and AstraZeneca vaccinated individuals.17,18 A recent study reported an age-standardised incidence difference of 2.0 cases per 100,000 people vaccinated for BNT162b2 up to 42 days post-vaccination, which was lower than that of 4.8 additional cases per 100,000 people vaccinated with CoronaVac.19 Importantly, SARS-CoV-2 infection may pose a higher risk of Bell's palsy than vaccination. The underlying mechanisms for vaccine-related Bell's palsy are hypothesised to involve immune-mediated inflammation or reactivation of latent viruses, but these remain speculative and unproven.20 Regulatory agencies continue to closely monitor Bell's palsy cases through post-marketing surveillance. Despite this, the benefits of mRNA COVID-19 vaccines outweigh the risks, including any potential rare association with Bell's palsy.

This study demonstrates the non-inferiority of Comvigen compared to Comirnaty in neutralising antibody responses against wild-type and Omicron BA.4/BA.5, as supported by GMR analyses. Although higher GMTs and a greater proportion of participants achieving a >4-fold rise were observed with Comvigen against Omicron BA.4/BA.5, these difference were not statistically significant. Additionally, robust cellular immune responses were elicited by Comvigen, which may suggest enhanced protection against severe disease. These findings align with the results of other vaccines targeting WT/BA.4/BA.5 variants. For instance, in a study on the fourth dose of the BNT162b2 (bivalent) COVID-19 vaccine, administered 8–11 months after the third dose. GMTs against Omicron BA.4/BA.5 increased from 570 to 4456 (95% CI: 3852–5155) one month after the booster.21 In comparison, this study reports a GMT of psVNT against Omicron BA.4/BA.5 at Day 29 of 3909, despite a longer interval of 16 months between the last dose and the booster, suggesting that the interval between booster doses may influence immune response outcomes.

Similarly, mRNA1273.222 (bivalent, WT/BA.4/BA.5, 50 μg) as a second booster dose increased GMTs against wild type from 797 (95% CI: 679–936) to 7322 (95% CI: 6386–8396), with a GMFR of 9.2 (95% CI: 7.9–10.6).14 Although the wild-type GMT observed with mRNA-1273.222 exceed those reported in this study, differences in study populations, methodologies, assay platforms and the duration between the last dose to the booster (10 months in their study versus 16 months in ours) may account for these variations. Notably, GMTs against Omicron BA.4/BA.5 for mRNA1273.222 increased from 88 (95% CI: 72–107) to 2325 (95% CI: 1921–2813) by Day 29, which is lower than the GMT observed in this study for Comvigen (3909.8; 95% CI: 3515.0–4348.8).

The strengths of this study include its randomisation and comprehensive immunogenicity assessments, utilising multiple assays (psVNT-50, microVNT, ELISA for IgG and anti-Spike antibodies, and ELISpot for T-cell responses) to evaluate responses against various SARS-CoV-2 variants. Additionally, the study included detailed safety evaluations and features a relatively large and balanced sample size across both study arms, enhancing the reliability of the findings.

However, the study has limitations. Differences in vaccine doses (50 μg for Comvigen vs. 30 μg for Comirnaty) and varying intervals since prior vaccination may affect comparability. The relatively short follow-up period limited the assessment of immune response durability and the ability to detect rare adverse events. Furthermore, the study population, consisting primarily of healthy volunteers with high prior vaccination rates, constrains generalisability to broader populations. Although the study was randomised, there were some imbalances in baseline characteristics between groups, particularly in the proportion of participants with a history of COVID-19 infection and in sex distribution. These differences may introduce residual confounding and should be considered when interpreting the findings. The open-label design may introduce bias in the reporting of subjective safety outcomes; however, the primary objective immunogenicity assessments were conducted in a blinded laboratory, and safety data were collected using standardised procedures to minimise reporting bias. The generalisability of our findings may be limited by the demographic profile of the study population, which consisted primarily of healthy adults aged 18–65 years, with limited representation of older adults and individuals with comorbidities. While immune responses were consistent across age and gender subgroups, the underrepresentation of high-risk populations may affect the applicability of the results to broader groups. Lastly, the study did not assess immunogenicity against newly emerging variants due to the evolving nature of SARS-CoV-2.

Although Comvigen differs from the comparator vaccine, Comirnaty, in two key aspects—the use of a different lipid nanoparticle (LNP) formulation and an mRNA encoding only the ectodomain of the non-stabilised wild-type SARS-CoV-2 spike protein—its safety and immunogenicity profiles were comparable. Therefore, Comvigen is unlikely to confer additional clinical advantages. However, its development offers important benefits in terms of freedom-to-operate and demonstrates Thailand's capability, as a low- and middle-income country (LMIC), to develop and manufacture a high-quality bivalent mRNA vaccine locally. This highlights the feasibility and importance of building mRNA vaccine R&D and manufacturing capacity in LMICs to address future pandemic threats and promote equitable access to vaccines for other unmet medical needs.22

Thailand's COVID-19 mRNA vaccine development program has proven this approach is feasible through several key factors: strong scientific and technical support from top scientists at the University of Pennsylvania, transformative strategic funding from the Thai government and the National Vaccine Institute, innovative LNP licencing by Genevant Sciences GmbH (Switzerland), the enhancement of existing local vaccine manufacturing capacity at BioNet-Asia (Thailand), and the unwavering commitment of researchers at Chulalongkorn University (Chula VRC). Beyond COVID-19 vaccines, this successful capacity-building effort is now being expanded to develop up to 10 additional vaccine candidates to address vaccine equity by targeting unmet needs. Furthermore, regional collaborative initiatives are being established to advance global pandemic preparedness and equitable vaccine access.23, 24, 25

Comvigen is safe, well-tolerated, and induces a robust immune response. It produces high levels of neutralising antibodies and T-cell activation against both wild-type SARS-CoV-2 and Omicron BA.4/BA.5 variants. The immune response is comparable to currently approved mRNA vaccines. Thailand's COVID-19 vaccine development program demonstrates the feasibility of a low- and middle-income country (LMIC) in establishing an mRNA vaccine platform, contributing to global efforts for future pandemic preparedness and vaccine equity.

Contributors

WJ, TP, SG, AA, SP, TT, SN, AT, SB, AJ, CK, EP, SL, and KR contributed to the study design. WJ, RN, TP, SG, AA, SP, TT, and SN were responsible for participant recruitment, data collection, and clinical assessments. AJ, DW, MGA, and KR provided vaccine development and immunological analysis expertise. Laboratory analyses were performed by SB, CK, EP, and AT. SL and the BioPHICS team verified the data. SL conducted the statistical analyses. LH, MS, and WW provided vaccine formulation, manufacturing, and quality controls expertise. WJ, RN, TP, and KR drafted the manuscript with input from all authors. All authors critically reviewed and approved the final manuscript. WJ and KR had full access to all data in the study and take final responsibility for the decision to submit for publication.

Data sharing statement

Deidentified individual participant data will be made available upon reasonable request. The study protocol, statistical analysis plan, and informed consent form will also be accessible. Data will be available beginning six months after publication and for a period of five years. Access will be granted to researchers whose proposals are approved by the study steering committee. Requests should be directed to Kiat Ruxrungtham (kiat.r@chula.ac.th); data sharing will require a signed data access agreement.

Declaration of interests

WJ, RN, TP, SG, AA, SP, TT, SN, AT, SB, AJ, CK, EP, SL, WW, DW, MGA, and KR—no conflict of interest to declare. LH and MS are paid employees by Genevant Science GmbH.

Acknowledgements

The funding source had no role in the design, conduct, analysis, or reporting of the trial. Funding included the COVID-19 Pandemic Emergency Fund, granted by Thailand's National Economic and Social Development Council, which provided major funding. Supplementary funding was provided by National Vaccine Institute (NVI), Thailand; Center of Excellence in Vaccine Research and Development (Chula VRC), Faculty of Medicine, Chulalongkorn University; Chulalongkorn University Second Century Fund (C2F); BioNet-Asia and Public Donation through COVID-19 vaccine development fund of the Faculty of Medicine, Chulalongkorn University and the Thai Red Cross Society, Thailand.

Footnotes

Trial registry: ClinicalTrials.gov ID NCT05930730.

Appendix A

Supplementary data related to this article can be found at https://doi.org/10.1016/j.lansea.2025.100650.

Contributor Information

Kiat Ruxrungtham, Email: kiat.r@chula.ac.th.

ChulaVac006 Study Team:

Wanida Wichaisak, Kanipha Sriphraram, Thanakan Rachpradit, Kwanhathai Chaiprom, Nittaya Boonnak, Chomnid Shanyib, Supapit Horpratum, Papassorn Kingklao, Siriwan Thongthip, Angwara Jintabunditwong, Kanchana Prasith, Aphakan Klinsukontakul, Chiratchaya Pornpipatkarn, Nuttamon Siripong, Supasek Laosuebsakul, Nongluk Ratmanee, Ratmanee Puttasuwan, Supalak Phonphithak, Naruporn Kasipong, Jirapohn Onaree, Sasiwimol Ubolyam, Apicha Mahanontharit, Apichaya Khlaiphuengsin, Nuchtida Phongam, Bunruan Sopa, Palida Pingthaisong, Prapaporn Savaraj, Siriluck Teerachia, Nitiya Tarun, Kamonwan Siriwatthanakul, Nattiya Arthonchaikul, Saowarot Chaimala, Thanphet Tantawichien, Chanitra Kohloi, Yupadee Jareonsawad, Decha Puangbaidee, Prach Chinnarat, Apichaya Wattanasathean, Kannika Damkoengkhachonwong, Roongrawee Sriaksorn, Ketkanhok Nisungnoen, Tharini Sisupha, Wichai Sritangkum, Vitoon Vonghangool, Hong Thai Pham, Souad Mansouri, Jesada Sathainsoontorn, Ladda Suwitruengrit, Mukesh Chauhan, Woranut Suksotkhiao, Daraporn Pittayakhajonwut, Wasin Buasri, and Nanthida Wonglertnirant

Appendix A. Supplementary data

ChulaVac006 Final analysis SAP version 1.0_17SEP2024
mmc1.pdf (3.6MB, pdf)
Appendix
mmc2.docx (15.1KB, docx)
Pubmed Table
mmc3.docx (17.9KB, docx)
Supplement Tables
mmc4.docx (37.3KB, docx)
ChulaCov006_PRT Ver 5.0 Date 7 Nov 2023_Final
mmc5.pdf (2.5MB, pdf)

References

  • 1.Lee J., Woodruff M.C., Kim E.H., Nam J.H. Knife's edge: balancing immunogenicity and reactogenicity in mRNA vaccines. Exp Mol Med. 2023;55(7):1305–1313. doi: 10.1038/s12276-023-00999-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.World Health Organization WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/vaccines?n=o Available from:
  • 3.Nabaggala M.S., Nair T.S., Gacic-Dobo M., Siyam A., Diallo K., Boniol M. The global inequity in COVID-19 vaccination coverage among health and care workers. Int J Equity Health. 2022;21(Suppl 3):147. doi: 10.1186/s12939-022-01750-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.World Health Organization Establishment of a COVID-19 mRNA vaccine technology transfer hub to scale up global manufacturing. 2021. https://www.who.int/news-room/articles-detail/establishment-of-a-covid-19-mrna-vaccine-technology-transfer-hub-to-scale-up-global-manufacturing Available from:
  • 5.Torreele E., Wolfe D., Kazatchkine M., et al. From private incentives to public health need: rethinking research and development for pandemic preparedness. Lancet Glob Health. 2023;11(10):e1658–e1666. doi: 10.1016/S2214-109X(23)00328-5. [DOI] [PubMed] [Google Scholar]
  • 6.Prompetchara E., Ketloy C., Alameh M.G., et al. Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. Nat Commun. 2023;14(1):2309. doi: 10.1038/s41467-023-37795-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gatechompol S., Kittanamongkolchai W., Ketloy C., et al. Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial. Nat Microbiol. 2022;7(12):1987–1995. doi: 10.1038/s41564-022-01271-0. [DOI] [PubMed] [Google Scholar]
  • 8.Puthanakit T., Prompetchara E., Gatechompol S., et al. Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study. Sci Rep. 2024;14(1):2373. doi: 10.1038/s41598-023-49653-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World Health Organization Update on Omicron. https://www.who.int/news/item/28-11-2021-update-on-omicron Available from:
  • 10.Heyes J., Hall K., Tailor V., Lenz R., MacLachlan I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release. 2006;112(2):280–290. doi: 10.1016/j.jconrel.2006.02.012. [DOI] [PubMed] [Google Scholar]
  • 11.Lam K., Leung A., Martin A., et al. Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle components for therapeutic and vaccine applications. Adv Mater. 2023;35(15) doi: 10.1002/adma.202209624. [DOI] [PubMed] [Google Scholar]
  • 12.Heyes J., Judge A., Lam K.M., Palmer L.R., Schreiner P. Lipid Nanoparticle formulations. WO2020/097540 A1. World Intellectual Property Organization; Geneva, Switzerland: 2020. [Google Scholar]
  • 13.World Health Organization Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Technical Report Series 1004, Annex 9. 2017. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9 Available from:
  • 14.Chalkias S., Whatley J.L., Eder F., et al. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results. Nat Med. 2023;29(9):2325–2333. doi: 10.1038/s41591-023-02517-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Pandit T., Pandit R., Goyal L. Uncommon side effects of COVID-19 vaccination in the pediatric population. Cureus. 2022;14(10) doi: 10.7759/cureus.30276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Collins R.A., Ray N., Ratheal K., Colon A. Severe post-COVID-19 costochondritis in children. Proc (Bayl Univ Med Cent) 2022;35(1):56–57. doi: 10.1080/08998280.2021.1973274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gordon A.J., Varelas A., Eytan D.F. Bell's palsy after vaccination against covid-19: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2023;169(5):1114–1121. doi: 10.1002/ohn.385. [DOI] [PubMed] [Google Scholar]
  • 18.Rafati A., Pasebani Y., Jameie M., et al. Association of SARS-CoV-2 vaccination or infection with Bell palsy: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2023;149(6):493–504. doi: 10.1001/jamaoto.2023.0160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wan E.Y.F., Chui C.S.L., Lai F.T.T., et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64–72. doi: 10.1016/S1473-3099(21)00451-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Cellina M., D'Arrigo A., Floridi C., Oliva G., Carrafiello G. Left Bell's palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: a case report. Clin Imaging. 2022;82:1–4. doi: 10.1016/j.clinimag.2021.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Usdan L., Patel S., Rodriguez H., et al. A bivalent Omicron-BA.4/BA.5-adapted BNT162b2 booster in >/=12-year-olds. Clin Infect Dis. 2024;78(5):1194–1203. doi: 10.1093/cid/ciad718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Farlow A., Torreele E., Gray G., et al. The future of epidemic and pandemic vaccines to serve global public health needs. Vaccines (Basel) 2023;11(3):690. doi: 10.3390/vaccines11030690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.World Health Organization WHO/MPP mRNA R&D consortium in SEA. The first meeting, Bangkok, Thailand. 2023. https://iris.who.int/bitstream/handle/10665/376746/SEA-HSD-403-eng.pdf?sequence=1 Available from:
  • 24.World Health Organization WHO/MPP mRNA R&D consortium in SEA. The second meeting in Singapore. 2024. https://www.who.int/news-room/events/detail/2024/03/18/default-calendar/who-mpp-mrna-r-d-consortia-in-south-east-asia Available from:
  • 25.UK-South-East Asia vaccine manufacturing research hub (UK-SEA Vax hub) https://ukseavaxhub.org Available from:

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ChulaVac006 Final analysis SAP version 1.0_17SEP2024
mmc1.pdf (3.6MB, pdf)
Appendix
mmc2.docx (15.1KB, docx)
Pubmed Table
mmc3.docx (17.9KB, docx)
Supplement Tables
mmc4.docx (37.3KB, docx)
ChulaCov006_PRT Ver 5.0 Date 7 Nov 2023_Final
mmc5.pdf (2.5MB, pdf)

Articles from The Lancet Regional Health - Southeast Asia are provided here courtesy of Elsevier

RESOURCES